ESMO Open最新文献_第8页

86P Functional impact of miR-205-5p on cervical cancer cell behavior and chemotherapy response 86P miR-205-5p 对宫颈癌细胞行为和化疗反应的功能影响

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103827

引用次数: 0

88P Impact of poly(ADP-ribose) polymerase (PARP) mutations on interaction with PARP inhibitors (iPARPs) 88P 多（ADP-核糖）聚合酶（PARP）突变对与 PARP 抑制剂（iPARPs）相互作用的影响

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103829

引用次数: 0

21P Improving early cancer screening efficacy by adjusting tumor burden spectrum bias of liquid biopsy biomarkers 21P 通过调整液体生物标记物的肿瘤负荷谱偏差提高早期癌症筛查效率

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103767

引用次数: 0

11P A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia 11P 一项评估原发性急性髓性白血病 SLC40A1 基因预后意义和分子机制的前瞻性研究

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103757

引用次数: 0

3O Pre-clinical pan-cancer drug repurposing via deep learning 3O 通过深度学习进行临床前泛癌症药物再利用

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103749

引用次数: 0

28P Clinical significance of TROP2 expression in lung adenocarcinomas 28P TROP2 在肺腺癌中表达的临床意义

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103774

引用次数: 0

52P RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis 52P RAS突变状态和突变类型作为转移性结直肠癌血栓形成的潜在预测生物标志物：三级中心12年队列分析

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103797

引用次数: 0

13P Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort 通过液滴数字 PCR 测定 BRCA1 和 RAD51C 启动子的 13P 甲基化可预测高级别浆液性卵巢癌患者的同源修复缺陷：在配对的 FFPE 和血浆样本中进行的 BOVARY 试点研究以及 ICL 卵巢队列的结果

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103759

引用次数: 0

79P Targeting galectin-9 in BRCA mutant breast cancer 79P 以 BRCA 突变乳腺癌中的 galectin-9 为靶点

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103820

引用次数: 0

Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets 晚期胆道癌不断演变的治疗格局：从化疗到分子靶点。

IF 7.1 2区医学

ESMO Open Pub Date : 2024-10-01 DOI: 10.1016/j.esmoop.2024.103706

{"title":"Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets","authors":"","doi":"10.1016/j.esmoop.2024.103706","DOIUrl":"10.1016/j.esmoop.2024.103706","url":null,"abstract":"<div><div>Biliary tract cancer, the second most common type of liver cancer, remains a therapeutic challenge due to its late diagnosis and poor prognosis. In recent years, it has become evident that classical chemotherapy might not be the optimal treatment for patients with biliary tract cancer, especially after failure of first-line therapy. Finding new treatment options and strategies to improve the survival of these patients is therefore crucial. With the rise and increasing availability of genetic testing in patients with tumor, novel treatment approaches targeting specific genetic alterations have recently been proposed and have demonstrated their safety and efficacy in numerous clinical trials. In this review, we will first consider chemotherapy options and the new possibility of combining chemotherapy with immune checkpoint inhibitors in first-line treatment. We will then provide an overview of genomic alterations and their potential for targeted therapy especially in second-line therapy. In addition to the most common alterations such as isocitrate dehydrogenase 1 or 2 (<em>IDH</em>1/2) mutations, fibroblast growth factor receptor 2 (<em>FGFR2</em>) fusions, and alterations, we will also discuss less frequently encountered alterations such as <em>BRAF</em> V600E mutation and neurotrophic tyrosine kinase receptor gene (<em>NTRK</em>) fusion. We highlight the importance of molecular profiling in guiding therapeutic decisions and emphasize the need for continued research to optimize and expand targeted treatment strategies for this aggressive malignancy.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0